



RealRate


PHARMACEUTICAL 2022











The relative strengths and weaknesses of SUPERNUS PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SUPERNUS PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 235% points. The greatest weakness of SUPERNUS PHARMACEUTICALS INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 86%, being 362% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	601,590
Cost of Goods Sold	0
Intangible Assets	902,209
Liabilities, Current	315,379
Liabilities, Non-Current	57,678
Other Assets	185,353
Other Compr. Net Income	-7,436
Other Expenses	118,271
Other Liabilities	500,244
Other Net Income	-12,854
Property and Equipment	0
Research and Development	90,467
Revenues	579,775
Selling, General and Administrative Expense	304,759

Output Variable	Value in 1000 USD
Assets	1,689,152
Liabilities	873,301
Expenses	513,497
Stockholders Equity	815,851
Net Income	53,424
Comprehensive Net Income	49,706
Economic Capital Ratio	86%

